Scientists at ORNL used their expertise in quantum biology, artificial intelligence and bioengineering to improve how CRISPR Cas9 genome editing tools work on organisms like microbes that can be modified to produce renewable fuels and chemicals.
Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.
Timothy Gray of ORNL led a study that may have revealed an unexpected change in the shape of an atomic nucleus. The surprise finding could affect our understanding of what holds nuclei together, how protons and neutrons interact and how elements form.
Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
Led by Kelly Chipps of ORNL, scientists working in the lab have produced a signature nuclear reaction that occurs on the surface of a neutron star gobbling mass from a companion star. Their achievement improves understanding of stellar processes generating diverse nuclear isotopes.
Kelly Chipps, a nuclear astrophysicist at ORNL, has been appointed to the Nuclear Science Advisory Committee, or NSAC. The committee provides official advice to DOE and the National Science Foundation, or NSF, about issues relating to the national program for basic nuclear science research.
Andrew Lupini, a scientist and inventor at ORNL, has been elected Fellow of the Microscopy Society of America.
Researchers at ORNL have developed a machine-learning inspired software package that provides end-to-end image analysis of electron and scanning probe microscopy images.
An ORNL-led team's observation of certain crystalline ice phases challenges accepted theories about super-cooled water and non-crystalline ice. Their findings, reported in the journal Nature, will also lead to better understanding of ice and its various phases found on other planets, moons and elsewhere in space.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.